{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:17:49Z","timestamp":1767212269583},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>LAA occlusion has become a favourable option in patients with atrial fibrillation not eligible for oral anticoagulation therapy. Proof of effectiveness of LAA closure devices in a midterm follow-up period. This retrospective single-center cohort study analysed outcome in patients treated with AMPLATZER Cardiac Plug or AMPLATZER Amulet device. A standardized follow-up by phone call focusing on data of death, stroke and bleeding events was performed. Routine antiplatelet strategy was DAPT for 3\u00a0months post procedural. 212 patients (mean age 77\u2009\u00b1\u20096\u00a0years) were included. Follow up was performed in 197 (93%) patients. Patients were at high risk for thromboembolic or bleeding events (prior stroke\/TIA 29%; prior bleeding 54%. Overall, there was a mean follow-up period of 1244.2\u00a0days (\u00b1\u2009756.7) and a total of 674 patient years. We observed 25 events later than day 8 post procedure. We were able to demonstrate a high effectiveness of the AMPLATZER Cardiac Plug\/AMPLATZER Amulet devices regarding the prevention of stroke and bleedings in a high-risk real-world cohort during a midterm follow-up period. Overall, we observed remarkably lower rates of stroke and bleedings as predicted with CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>\u2013VASc and HASBLED scores.<\/jats:p>","DOI":"10.1038\/s41598-020-73381-w","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T10:05:01Z","timestamp":1601546701000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Midterm outcomes of LAA occlusion with the AMPLATZER Cardiac Plug and AMPLATZER Amulet devices in a high-risk cohort"],"prefix":"10.1038","volume":"10","author":[{"given":"Tobias","family":"Tichelb\u00e4cker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Scherner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Puls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Schillinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Jacobshagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"H\u00fcnlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"73381_CR1","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof, P. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 37, 2893\u20132962 (2016).","journal-title":"Eur. Heart J."},{"key":"73381_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger, C. B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981\u2013992 (2011).","journal-title":"N. Engl. J. Med."},{"key":"73381_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel, M. R. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883\u2013891 (2011).","journal-title":"N. Engl. J. Med."},{"key":"73381_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139\u20131151 (2009).","journal-title":"N. Engl. J. Med."},{"key":"73381_CR5","doi-asserted-by":"publisher","first-page":"e0195950","DOI":"10.1371\/journal.pone.0195950","volume":"13","author":"GYH Lip","year":"2018","unstructured":"Lip, G. Y. H. et al. Discontinuation risk comparison among \u2018real-world\u2019 newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban. PLoS ONE 13, e0195950 (2018).","journal-title":"PLoS ONE"},{"key":"73381_CR6","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","volume":"70","author":"VY Reddy","year":"2017","unstructured":"Reddy, V. Y. et al. 5-Year outcomes after left atrial appendage closure. J. Am. Coll. Cardiol. 70, 2964\u20132975 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"73381_CR7","first-page":"1170","volume":"11","author":"A Tzikas","year":"2016","unstructured":"Tzikas, A. et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention J. Eur. Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol. 11, 1170\u20131179 (2016).","journal-title":"EuroIntervention J. Eur. Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol."},{"key":"73381_CR8","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"Developed with the special contribution of the European Heart Rhythm Association (EHRA)","year":"2010","unstructured":"Developed with the special contribution of the European Heart Rhythm Association (EHRA) et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 31, 2369\u20132429 (2010).","journal-title":"Eur. Heart J."},{"issue":"1","key":"73381_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/europace\/euw141","volume":"19","author":"A Tzikas","year":"2017","unstructured":"Tzikas, A. et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace 19(1), 4\u201315. https:\/\/doi.org\/10.1093\/europace\/euw141 (2017).","journal-title":"Europace"},{"key":"73381_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijcard.2017.07.052","volume":"248","author":"S Berti","year":"2017","unstructured":"Berti, S. et al. Left atrial appendage closure using AMPLATZER devices: a large, multicenter Italian registry. Int. J. Cardiol. 248, 103\u2013107 (2017).","journal-title":"Int. J. Cardiol."},{"key":"73381_CR11","doi-asserted-by":"publisher","first-page":"e590","DOI":"10.4244\/EIJ-D-18-00344","volume":"14","author":"U Landmesser","year":"2018","unstructured":"Landmesser, U. et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. EuroIntervention 14, e590\u2013e597 (2018).","journal-title":"EuroIntervention"},{"key":"73381_CR12","first-page":"213","volume":"7","author":"N Messas","year":"2018","unstructured":"Messas, N. & Ibrahim, R. The Amplatzer Amulet Device. Interv. Cardiol. Clin. 7, 213\u2013218 (2018).","journal-title":"Interv. Cardiol. Clin."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73381-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73381-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73381-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:23:13Z","timestamp":1670358193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73381-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73381"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73381-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"1 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16323"}}